OrthoPediatrics (KIDS) Expected to Announce Earnings on Thursday
OrthoPediatrics (NASDAQ:KIDS) is expected to announce its Q4 2025 earnings after the market closes on Thursday, February 26th, 2026. Analysts project a loss of ($0.29) per share on revenue of $61.27 million. The stock currently holds a "Moderate Buy" consensus rating with an average target price of $23.89, and institutional investors own approximately 69% of the shares.
OrthoPediatrics Corp. to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
OrthoPediatrics Corp. (Nasdaq: KIDS) announced it will release its fourth quarter and full year 2025 financial results on February 26, 2026, after the market closes. The company will also host a conference call on the same day at 4:30 p.m. ET to discuss the results, with a live and archived webcast available on its investor relations website. OrthoPediatrics focuses exclusively on pediatric orthopedics, offering over 85 products globally.
OrthoPediatrics Corp. to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
OrthoPediatrics Corp. (Nasdaq: KIDS) announced it will release its fourth quarter and full year 2025 financial results on February 26, 2026, after the market closes. The company will also host a conference call on the same day at 4:30 p.m. ET to discuss these results. A webcast of the event will be available on their investor relations website.
OrthoPediatrics Corp: Niche Pediatric Ortho Specialist Tests Investor Patience As Growth Story Repri
OrthoPediatrics Corp (KIDS), a specialized pediatric orthopedics company, is testing investor patience as its growth story reprices, with the stock trading in the lower half of its 52-week range despite solid revenue growth. Investors are grappling with the company's struggle to translate its clinical niche into sustained profitability and shareholder returns amid a cautious market for small-cap growth names. The future performance hinges on the company's ability to maintain revenue growth, convert innovations into market share gains, and navigate the broader economic landscape to achieve stronger profitability.
OrthoPediatrics Corp. to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
OrthoPediatrics Corp. (Nasdaq: KIDS) announced it will release its fourth quarter and full year 2025 financial results on Thursday, February 26, 2026, after the market closes. The company will also host a conference call at 4:30 p.m. ET on the same day to discuss these results. A live and archived webcast of the event will be available on the Investors page of their website.
OrthoPediatrics (KIDS): Niche Orthopedic Specialist Tests Investors’ Nerves After Steep Slide
OrthoPediatrics (KIDS), a pure-play pediatric orthopedics stock, has been experiencing a steep decline, trading near its 52-week low due to slower growth and high valuations. Investors are debating whether this presents a buying opportunity in a unique medical niche or signals a value trap. The company's unique focus on children's orthopedic care is balanced against market skepticism regarding execution risk and the absence of clear upside catalysts.
New York State Common Retirement Fund Has $3.54 Million Position in OrthoPediatrics Corp. $KIDS
The New York State Common Retirement Fund significantly reduced its stake in OrthoPediatrics Corp. (NASDAQ:KIDS) by 57.1% in the third quarter, now holding 191,066 shares valued at $3.54 million. Despite this reduction, institutional investors collectively own about 69.05% of the company's stock. OrthoPediatrics trades at $16.65, has a market cap of $417.6 million, and analysts maintain a "Moderate Buy" rating with an average target price of $23.89.
OrthoPediatrics Corp. (NASDAQ:KIDS) Given Average Rating of "Moderate Buy" by Brokerages
OrthoPediatrics Corp. (NASDAQ:KIDS) has received a consensus "Moderate Buy" rating from eleven brokerages, with an average 12-month price target of $23.89. The company's shares opened at $16.65, well below the target, indicating potential for growth. Recent analyst reports show adjustments in price targets but largely maintain positive ratings, with the company demonstrating strong liquidity and institutional ownership.
OrthoPediatrics Announces Expanded Enabling Technology Market Opportunity
OrthoPediatrics Corp. (Nasdaq: KIDS) announced that its partner, iotaMotion, received FDA 510(k) clearance for expanded pediatric use of its iotaSOFT® Insertion System. This system, which employs robotic-assisted technology for cochlear implantation, is now cleared for children four years of age and older. This expansion allows OrthoPediatrics to leverage its expertise beyond orthopedics and into the ENT space, with Cincinnati Children’s Hospital becoming the first dedicated pediatric center to adopt the iotaSOFT system.
OrthoPediatrics Up on iotaMotion Deal
OrthoPediatrics Corp. (NASDAQ: KIDS) saw its shares rise after its partner, iotaMotion, received FDA 510(k) clearance for expanded pediatric use of its iotaSOFT® Insertion System. This clearance allows the robotic-assisted cochlear implant system to be used in children aged four and older, broadening access to advanced care in the ENT space. OrthoPediatrics CEO David Bailey highlighted that this partnership aligns with the company's mission to address unmet pediatric needs with cutting-edge technology.
OrthoPediatrics Announces Expanded Enabling Technology Market Opportunity
OrthoPediatrics announced that its partner, iotaMotion, received FDA clearance for expanded pediatric use of its iotaSOFT® Insertion System for cochlear implants in patients four years and older. This expands access to robotic-assisted cochlear implantation for school-aged children and allows OrthoPediatrics to broaden its impact in the ENT space through its Enabling Technologies division. Cincinnati Children’s Hospital has already adopted the system, joining over 35 other leading cochlear implant centers.
Robot-assisted cochlear implants now cleared for kids 4+
OrthoPediatrics' partner iotaMotion has received FDA 510(k) clearance to expand the use of its iotaSOFT® cochlear implant insertion system to patients four years and older. This clearance will broaden access to robotic-assisted cochlear implantation for school-aged children. Cincinnati Children's Hospital has become the first dedicated pediatric center to adopt iotaSOFT, joining over 35 other U.S. cochlear implant centers already using the technology.
OrthoPediatrics and iotaMotion Announce FDA Clearance for Expanded Pediatric Use of iotaSOFT® Insertion System
OrthoPediatrics Corp. and iotaMotion announced that iotaMotion's iotaSOFT® Insertion System has received FDA 510(k) clearance for expanded pediatric use in children aged four and older, enabling robotic-assisted cochlear implantation. This system is the first FDA-authorized open-platform robotic technology designed to improve the consistency and speed of cochlear implant insertion. Cincinnati Children's Hospital is the first dedicated pediatric center to adopt this technology, marking a strategic expansion for OrthoPediatrics into new areas of pediatric care beyond orthopedics.
OrthoPediatrics Announces Expanded Enabling Technology Market Opportunity
OrthoPediatrics announced that its partner, iotaMotion, received FDA clearance for expanded pediatric use of its iotaSOFT® Insertion System. This clearance allows the system, which provides robotic-assisted cochlear implantation, to be used in patients four years of age and older. The expanded access through this partnership is part of OrthoPediatrics' strategy to extend its pediatric-first expertise beyond orthopedics and into adjacent areas of pediatric care.
Brown Capital Management LLC Decreases Holdings in OrthoPediatrics Corp. $KIDS
Brown Capital Management LLC has reduced its stake in OrthoPediatrics Corp. (NASDAQ:KIDS) by 30.5% in the third quarter of 2025, now holding 1,081,220 shares valued at approximately $20.04 million. Despite the institutional sell-off, OrthoPediatrics currently trades around $17.29, with analysts maintaining a "Moderate Buy" consensus rating and a target price of $23.89. Institutional investors collectively own about 69.05% of the company's stock.
OrthoPediatrics (NASDAQ:KIDS) Rating Increased to Strong-Buy at TD Cowen
TD Cowen upgraded OrthoPediatrics (NASDAQ:KIDS) to a "strong-buy" rating, although the overall analyst consensus remains a "Moderate Buy" with an average price target of $23.89. The company recently reported Q4 EPS of ($0.24) (beating estimates by $0.02) on revenue of $61.25 million, with shares currently trading around $17.74. OrthoPediatrics has a market cap of $444.92 million, a negative P/E ratio of -9.10, and analysts expect a full-year EPS of -0.93.
TD Cowen initiates coverage on OrthoPediatrics stock with Buy rating
TD Cowen has initiated coverage on OrthoPediatrics Corp. (NASDAQ:KIDS) with a Buy rating and a $23.00 price target, recognizing the company as a leader in pediatric orthopedics due to its innovation and market positioning. The firm anticipates sustained low-double-digit revenue growth and improved EBITDA, believing the company's current valuation does not reflect its potential. This positive outlook follows OrthoPediatrics' record revenue in 2025 and expansion of its bracing portfolio, despite some recent analyst target adjustments reflecting growth concerns.
KIDS: TD Cowen Initiates Coverage with a Buy Rating and $23 PT
TD Cowen has initiated coverage on OrthoPediatrics (KIDS) with a "Buy" rating and a price target of $23 USD. This comes amidst other recent analyst ratings, with an average target price from 8 analysts at $24.13, suggesting a potential upside of 35.69% from its current price of $17.78. GuruFocus estimates a fair value of $47.63 for OrthoPediatrics, indicating an even larger potential upside.
TD Cowen initiates coverage on OrthoPediatrics stock with Buy rating
TD Cowen has initiated coverage on OrthoPediatrics Corp. (NASDAQ:KIDS) with a Buy rating and a $23.00 price target, citing the company's leadership in pediatric orthopedics, continuous innovation, and potential for sustained double-digit revenue growth. Despite recent analyst adjustments and some missed revenue targets, the firm believes the current valuation does not fully reflect these positive financial indicators. OrthoPediatrics also reported record revenue for 2025 and expanded its bracing portfolio.
OrthoPediatrics (NASDAQ:KIDS) Upgraded at Wall Street Zen
Wall Street Zen upgraded OrthoPediatrics (NASDAQ:KIDS) from a "sell" to a "hold" rating on Saturday. This upgrade contributes to a mixed but generally positive analyst sentiment, with eight "Buy," one "Hold," and one "Sell" rating, leading to a consensus "Moderate Buy" rating and a $24.00 price target. The company reported a Q4 EPS that beat estimates but missed revenue expectations, and institutional investors hold approximately 69% of its shares.
OrthoPediatrics Corp. (NASDAQ:KIDS) Receives Average Rating of "Moderate Buy" from Analysts
OrthoPediatrics Corp. (NASDAQ:KIDS) has received a consensus "Moderate Buy" rating from analysts, with an average 12-month price target of $24.00, based on 8 buy, 1 hold, and 1 sell recommendations. Despite beating EPS estimates in its latest quarter, the company missed revenue estimates and remains unprofitable. Institutional investors hold approximately 69% of the company's stock, with several hedge funds adjusting their positions recently.
OrthoPediatrics Corp. Achieves Record Preliminary Unaudited Revenue for Full Year 2025 and Issues 2026 Financial Guidance
OrthoPediatrics Corp. announced record preliminary unaudited revenue of $236.1 million for the full year 2025, representing a 15% increase over 2024. The company also provided 2026 financial guidance, projecting revenue between $262 million to $266 million and approximately $25 million in Adjusted EBITDA. These achievements reflect strong performance in pediatric orthopedics, with significant contributions from trauma and deformity, scoliosis, and specialty bracing businesses.
How (KIDS) Movements Inform Risk Allocation Models
This article analyzes Orthopediatrics Corp. (NASDAQ: KIDS) using AI models, highlighting strong near and mid-term sentiment but a weak long-term outlook. It provides specific institutional trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis for support and resistance levels. The analysis suggests a breakout is underway with elevated downside risk long-term.
OrthoPediatrics Reports Record 2025 Revenue of $236.1 Million and Provides 2026 Financial Guidance
OrthoPediatrics reported record preliminary unaudited revenue of $236.1 million for 2025, a 15% increase from the previous year, and announced financial guidance for 2026 projecting revenue between $262 million and $266 million. The company also anticipates generating approximately $25 million in Adjusted EBITDA for 2026 and highlighted its continued impact, having helped nearly 1.3 million children since its inception. While showcasing strong growth, the 2026 growth projection of 11-13% represents a deceleration compared to 2025's 15%.
OrthoPediatrics Reports Record 2025 Revenue of $236.1 Million and Provides 2026 Financial Guidance
OrthoPediatrics Corp. has announced record preliminary unaudited revenue of $236.1 million for 2025, a 15% increase from the previous year, driven by strong domestic and international growth. The company projects 2026 revenue to be between $262 million and $266 million, along with an Adjusted EBITDA of approximately $25 million. OrthoPediatrics also highlighted its impact, having helped nearly 1.3 million children since its inception, and outlined strategic advancements in its Trauma and Deformity, Scoliosis, and specialty bracing businesses.
OrthoPediatrics reports record 2025 revenue of $236.1 million
OrthoPediatrics Corp. announced record annual revenue of $236.1 million for 2025, a 15% increase from the previous year, with projected revenue of $262 million to $266 million for 2026. The company also reported strong Q4 2025 results, improved free cash flow, and received EUMDR certification for several products. These financial updates come alongside recent analyst assessments and an expansion of its specialty bracing portfolio with two new hip devices.
OrthoPediatrics Corp. Achieves Record Preliminary Unaudited Revenue for Full Year 2025 and Issues 2026 Financial Guidance
OrthoPediatrics Corp. reported record preliminary unaudited revenue of $236.1 million for the full year 2025, a 15% increase over 2024, and $61.3 million for the fourth quarter of 2025. The company also issued positive financial guidance for 2026, projecting revenue between $262 million and $266 million and approximately $25 million in Adjusted EBITDA. This growth was driven by strong performance in its Trauma and Deformity and Scoliosis implant businesses, as well as the specialty bracing (OPSB) business.
OrthoPediatrics Corp. Achieves Record Preliminary Unaudited Revenue for Full Year 2025 and Issues 2026 Financial Guidance
OrthoPediatrics Corp. announced record preliminary unaudited revenue of $236.1 million for the full year 2025, representing a 15% growth over the prior year, and provided positive financial guidance for 2026. The company projects 2026 revenue to be between $262 million and $266 million and expects to generate approximately $25 million in Adjusted EBITDA. This strong performance is attributed to growth in Trauma and Deformity, Scoliosis implant businesses, and the OrthoPediatrics Specialty Bracing (OPSB) business.
OrthoPediatrics Corp. (KIDS) Stock Analysis: Healthcare Innovator with a 28.80% Potential Upside
OrthoPediatrics Corp. (KIDS) is highlighted as a medical device innovator specializing in pediatric orthopedics, with a current stock price of $18.73 and a potential upside of 28.80% to its average target price of $24.13. Despite challenges like a negative EPS and P/E ratio, reflecting a growth-centric strategy, analyst sentiment is largely positive, with a strong focus on market expansion and product innovation. The company's unique market niche and diverse product portfolio position it for future growth in the healthcare sector.
The Truth About OrthoPediatrics Corp (KIDS): Tiny Stock, Huge Bet – or Total Flop?
This article analyzes OrthoPediatrics Corp (KIDS), a specialized medical device company focusing on pediatric orthopedic care. It explores whether this niche stock represents a significant investment opportunity or a high-risk venture, highlighting its specialization, long-term growth potential, and inherent risks due to its small size and market focus. The author advises that KIDS is suitable for long-term, impact-driven investors rather than those seeking quick returns or viral hype.
The Truth About OrthoPediatrics Corp (KIDS): Tiny Stock, Huge Bet – or Total Flop?
OrthoPediatrics Corp (KIDS) is a niche medical device company focused on pediatric orthopedic care, which, despite not being a viral stock, is gaining attention among healthcare investors. The company specializes in creating medical devices for children's bones and growth plates, differentiating itself from larger competitors that primarily serve adults. While it represents a long-term growth opportunity and impact investment, its specialization also makes it susceptible to market volatility and competition, making it less suitable for short-term traders.
Harbor Capital Advisors Inc. Has $1.94 Million Position in OrthoPediatrics Corp. $KIDS
Harbor Capital Advisors Inc. significantly reduced its stake in OrthoPediatrics Corp. (NASDAQ:KIDS) by 68.7% in the third quarter, bringing its total holding to 104,689 shares valued at $1.94 million. Despite this reduction and recent downward adjustments to price targets by several firms, analysts generally maintain a "Moderate Buy" rating for the stock, with a consensus target price of $24.00. OrthoPediatrics, trading at $17.42 with a market cap of approximately $436.9 million, reported a negative EPS of ($0.15) for the latest quarter.
(KIDS) as a Liquidity Pulse for Institutional Tactics
This article analyzes Orthopediatrics Corp. (NASDAQ: KIDS), highlighting a weak sentiment across all time horizons that supports a short bias. It details an exceptional 42.6:1 risk-reward short setup and outlines three distinct AI-generated trading strategies tailored to various risk profiles and holding periods. The analysis also includes multi-timeframe signal insights and offers real-time trading signals and institutional-grade analysis for subscribers.
OrthoPediatrics Corp. (NASDAQ:KIDS) Given Average Recommendation of "Moderate Buy" by Brokerages
OrthoPediatrics Corp. (NASDAQ:KIDS) has received a consensus "Moderate Buy" rating from ten brokerages, with an average 1-year price target of $24.00. The company reported quarterly EPS of -$0.15 on $25.08 million in revenue and analysts forecast EPS of -0.93 for the current year. Institutional investors hold approximately 69.05% of the stock.
OrthoPediatrics (NASDAQ:KIDS) Now Covered by Canaccord Genuity Group
Canaccord Genuity Group has initiated coverage on OrthoPediatrics (NASDAQ:KIDS) with a "buy" rating and a $24.00 price target, suggesting a potential upside of over 30%. Despite this optimistic outlook, OrthoPediatrics remains unprofitable, posting an EPS of -$0.15 last quarter and an expected -0.93 EPS for the current year. The company has a current market capitalization of approximately $459.72 million.
OrthoPediatrics (NASDAQ:KIDS) Upgraded by Wall Street Zen to "Hold" Rating
Wall Street Zen has upgraded OrthoPediatrics (NASDAQ:KIDS) from a "sell" to a "hold" rating, contributing to a "Moderate Buy" consensus among analysts with an average price target of $24.00. Despite recent price target cuts from some firms, other analysts continue to maintain "Buy" ratings, showcasing mixed sentiment. The company reported negative earnings last quarter and operates with a negative net margin, while institutional investors have recently increased their holdings.
Brown Capital Management LLC Decreases Stake in OrthoPediatrics Corp. $KIDS
Brown Capital Management LLC reduced its stake in OrthoPediatrics Corp. by 6.8% in Q2, ending with 1,556,704 shares valued at approximately $33.44 million. Despite the institutional selling and negative financial metrics, analyst sentiment remains mixed but generally positive, with a "Moderate Buy" consensus rating and a $24 average target price. This comes as OrthoPediatrics faces a negative EPS projection for the current fiscal year.
21,066 Shares in OrthoPediatrics Corp. $KIDS Purchased by Grandeur Peak Global Advisors LLC
Grandeur Peak Global Advisors LLC recently acquired 21,066 shares of OrthoPediatrics Corp. (NASDAQ:KIDS) valued at approximately $452,000, establishing a new position and contributing to institutional investors owning 69.05% of the company. Despite a "Moderate Buy" consensus rating from analysts, several firms have recently lowered their price targets for KIDS. OrthoPediatrics, trading near $18.49, faces financial challenges including recent quarterly losses and a negative net margin.
OrthoPediatrics (NASDAQ:KIDS) Is Making Moderate Use Of Debt
OrthoPediatrics (NASDAQ:KIDS) utilizes a moderate amount of debt, with US$99.3m in debt as of September 2025, offset by US$57.7m in cash, resulting in net debt of US$41.6m. While its liabilities outweigh current cash and receivables by US$35.2m, its market cap of US$447.6m suggests this isn't a major threat. However, the company is not currently profitable at an EBIT level, posting a US$32m loss, and had negative free cash flow of US$29m, indicating some financial risk despite revenue growth.
OrthoPediatrics (NASDAQ: KIDS) launches two PediHip braces for DDH ages three and younger
OrthoPediatrics (NASDAQ: KIDS) has expanded its OrthoPediatrics Specialty Bracing (OPSB) portfolio by introducing two new PediHip products: the Rigid Brace and the Modular Abduction System. These products, developed with pediatric hip experts, are designed to treat developmental dysplasia of the hip (DDH) and provide post-operative stabilization for children aged three and younger. The launch increases OrthoPediatrics' OPSB division to 31 systems, further addressing the full pediatric hip care continuum.
OrthoPediatrics Corp. Expands Specialty Bracing Portfolio with Two New Product Launches
OrthoPediatrics Corp. (Nasdaq: KIDS) has expanded its OrthoPediatrics Specialty Bracing (OPSB) portfolio with the launch of two new products: the PediHip™ Rigid Brace and PediHip™ Modular Abduction Systems. These products are designed for the treatment of Developmental Dysplasia of the Hip (DDH) and post-operative stabilization in pediatric patients aged three and younger. The expansion brings the company's OPSB division to 31 systems, enhancing current treatment options for pediatric hip care.
OrthoPediatrics Corp. Expands Specialty Bracing Portfolio with Two New Product Launches
OrthoPediatrics Corp. has expanded its Specialty Bracing (OPSB) portfolio with the introduction of two new products: the PediHip™ Rigid Brace and PediHip™ Modular Abduction Systems. Developed in collaboration with pediatric hip experts, these products are designed for treating Developmental Dysplasia of the Hip (DDH) and providing post-operative stabilization in pediatric patients aged three and younger, enhancing current treatment options. This expansion brings the company's OPSB division to 31 systems, reinforcing its commitment to advancing pediatric orthopedic care.
OrthoPediatrics Corp. Receives FDA approval for 3P™ Pediatric Plating Platform™ Small-Mini System, the second of several systems in the 3P family
OrthoPediatrics Corp. has received FDA approval for its 3P™ Pediatric Plating Platform™ Small-Mini System, marking its sixth FDA approval in 2025. This versatile system offers a plate and screw solution with variable-angle locking implants designed for pediatric orthopedic surgeons, supporting a wide range of procedures. The company aims for a limited market release in early 2026, further expanding its comprehensive portfolio of innovative orthopedic solutions for pediatric patients.
OrthoPediatrics to Participate in Upcoming Conferences
OrthoPediatrics Corp. (Nasdaq: KIDS) announced its participation in three upcoming investor conferences in November and December 2025. The company will engage in fireside chats at the Stifel 2025 Healthcare Conference and the Piper 37th Annual Healthcare Conference, and give a presentation at the Jeffries Global Healthcare Conference in London. Audio webcasts of these events will be available on the OrthoPediatrics investor relations website, with replays accessible for 90 days afterward.
OrthoPediatrics Corp. Reports Third Quarter 2025 Financial Results
OrthoPediatrics Corp. (Nasdaq: KIDS) announced its financial results for the third quarter ended September 30, 2025, reporting a 12% increase in total revenue to $61.2 million year-over-year and a 56% increase in Adjusted EBITDA to $6.2 million. The company's revenue guidance for the full year 2025 is $233.5 million to $234.5 million, representing 14% to 15% growth. Despite some shortfalls in 7D and Latin and South American markets, OrthoPediatrics continues to focus on strategic initiatives and new product introductions while aiming for free cash flow break-even in 2026.
OrthoPediatrics Corp. Receives FDA approval for 3P™ Pediatric Plating Platform™ Small-Mini System, the second of several systems in the 3P family
OrthoPediatrics Corp. (Nasdaq: KIDS) announced FDA approval for its 3P™ Pediatric Plating Platform™ Small-Mini System, marking the company's sixth FDA approval in 2025. This versatile plate and screw solution is designed for pediatric orthopedic surgeons, supporting a wide range of trauma and deformity surgeries with optimized operating room efficiency. It is the second system in the 3P Pediatric Plating Platform, following the 3P Hip System, with a limited market release expected in early 2026.
Understanding Momentum Shifts in (KIDS) - news.stocktradersdaily.com
This article analyzes Orthopediatrics Corp. (NASDAQ: KIDS), highlighting a potential shift from persistent mid and long-term weakness to a near-term strong sentiment. It identifies a mid-channel oscillation pattern and an exceptional 45.2:1 risk-reward setup, targeting a 13.5% gain with a 0.3% risk. The analysis includes AI-generated trading strategies for various risk profiles and multi-timeframe signal analysis, indicating current weak sentiment despite a strong near-term signal.
OrthoPediatrics Corp. to Report Third Quarter Financial Results on October 28, 2025 - The Manila Times
OrthoPediatrics Corp. (NASDAQ: KIDS) announced it will release its third-quarter 2025 financial results after the market closes on October 28, 2025. The company will also host a conference call and live webcast at 4:30 p.m. ET on the same day to discuss the results and provide an update on its business.
OrthoPediatrics Corp. to Report Third Quarter Financial Results on October 28, 2025 - Stock Titan
OrthoPediatrics Corp. (Nasdaq: KIDS) announced it will release its third-quarter 2025 financial results on October 28, 2025, after market close. The company will host a conference call on the same day at 4:30 p.m. ET to discuss these results. Investors can access a live and archived webcast of the event on the company's Investors page.
How Recent Developments Are Rewriting the Story for OrthoPediatrics - Yahoo Finance
OrthoPediatrics' consensus analyst price target has decreased significantly from $33.86 to $26.29 due to softer near-term revenue projections and market headwinds, despite strong core operations. The article outlines both bullish views, highlighting core business resilience and consistent management, and bearish concerns over multiple guidance revisions and macroeconomic risks. Key financial adjustments include moderated revenue growth, a slight decrease in net profit margin, and a lower future P/E ratio, urging investors to follow dynamic investment narratives to assess the company's evolving future.
